<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Xu Y</submitter><funding>National Natural Science Foundation of China</funding><pagination>784289</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8828472</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The efficacy of adjuvant chemotherapy in patients with 8th edition stage IB (tumor size ≤4 cm) non-small cell lung cancer (NSCLC) remains unclear.&lt;h4>Methods&lt;/h4>We identified 9757 eligible patients (non-chemotherapy group: n=8303; chemotherapy group: n=1454) between 2004 and 2016 from the Surveillance, Epidemiology and End Results (SEER) database. Log-rank test was used to compare overall survival (OS) between the chemotherapy and non-chemotherapy groups. Cox regression model was applied to investigate the independent prognosis factors of all surgically treated stage IB patients, and then the nomogram was constructed. Propensity score matching (PSM) was performed to reduce the confounding bias, and subgroup analyses of the matched cohort were also performed. Finally, we</pubmed_abstract><journal>Frontiers in oncology</journal><pubmed_title>Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer.</pubmed_title><pmcid>PMC8828472</pmcid><funding_grant_id>81401903, 81572937, 81572273</funding_grant_id><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Zhan P</pubmed_authors><pubmed_authors>Wan B</pubmed_authors><pubmed_authors>Zhang T</pubmed_authors><pubmed_authors>Xie J</pubmed_authors><pubmed_authors>Lv T</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors><pubmed_authors>Zhu S</pubmed_authors><pubmed_authors>Song Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer.</name><description>&lt;h4>Background&lt;/h4>The efficacy of adjuvant chemotherapy in patients with 8th edition stage IB (tumor size ≤4 cm) non-small cell lung cancer (NSCLC) remains unclear.&lt;h4>Methods&lt;/h4>We identified 9757 eligible patients (non-chemotherapy group: n=8303; chemotherapy group: n=1454) between 2004 and 2016 from the Surveillance, Epidemiology and End Results (SEER) database. Log-rank test was used to compare overall survival (OS) between the chemotherapy and non-chemotherapy groups. Cox regression model was applied to investigate the independent prognosis factors of all surgically treated stage IB patients, and then the nomogram was constructed. Propensity score matching (PSM) was performed to reduce the confounding bias, and subgroup analyses of the matched cohort were also performed. Finally, we</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2025-04-25T17:36:40.736Z</modification><creation>2025-04-25T17:36:40.736Z</creation></dates><accession>S-EPMC8828472</accession><cross_references><pubmed>35155190</pubmed><doi>10.3389/fonc.2021.784289</doi></cross_references></HashMap>